EQUASENS : Chiffre d’affaires du 3ème trimestre 2023
09 nov. 2023 12h00 HE
|
EQUASENS
Villers-lès-Nancy, le 9 novembre 2023 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires du 3ème trimestre 2023 Chiffre d’affaires du T3 2023 : stable comparée au T3 2022 à 50,1 M€La...
Equasens: Q3 2023 revenue
09 nov. 2023 12h00 HE
|
EQUASENS
Villers-lès-Nancy, 9 November 2023 - 6:00 p.m. (CET) PRESS RELEASE Q3 2023 revenue Q3 2023 revenue: stable year-on-year at €50.1mGrowth impacted by: The completed deployment of solutions under...
Egide: RESULTS FOR THE 1ST HALF OF 2023 MARK EGIDE GROUP'S RECOVERY
24 oct. 2023 12h33 HE
|
EGIDE
Press Release Bollène, October 24, 2023– 05:30pm (CET) RESULTS FOR THE 1ST HALF OF 2023MARK EGIDE GROUP'S RECOVERY _________________________________________________________________________________ ...
EGIDE : Résultats semestriels 2023 - Redressement du Groupe Egide
24 oct. 2023 11h55 HE
|
EGIDE
Communiqué de presse Bollène, le 24 octobre 2023– 17 :30 (CET) Les Résultats du 1er semestre 2023 marquent le redressement du Groupe Egide ...
CS Disco, Inc. Shareholders: Contact Robbins LLP for Information About the Firm's Investigation of LAW's Officers and Directors
24 oct. 2023 06h17 HE
|
Robbins LLP
CS Disco, Inc. (LAW) CEO Abruptly Left Company Following Complaints of Alleged Groping and Other Misconduct
CS Disco, Inc. (LAW) Stock News: Investors with Losses Should Contact Robbins LLP About Their Options Regarding the Class Action Lawsuit
23 oct. 2023 13h25 HE
|
Robbins LLP
CS Disco (LAW) Misled Investors Regarding its Business Prospects
EQUASENS : Résultats Semestriels 2023
29 sept. 2023 12h00 HE
|
EQUASENS
Villers-lès-Nancy, le 29 septembre 2023 - 18h00 (CET) COMMUNIQUE DE PRESSE Résultats Semestriels 2023 Croissance portée par une conjoncture favorable : Chiffre d’affaires : +8,7% à 112,6 M€...
EQUASENS: H1 2023 Results
29 sept. 2023 12h00 HE
|
EQUASENS
Villers-lès-Nancy, 29 September 2023 - 6:00 p.m. (CET) PRESS RELEASE H1 2023 Results Growth momentum bolstered by favourable market conditions: Revenue: €112.6m, +8.7% Current Operating Income:...
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. est une nouvelle société créée par Catalys Pacific, et dans laquelle Inventiva détient une participation de 30%. Dans le cadre de l’accord de licence exclusif, Inventiva...
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
20 sept. 2023 16h00 HE
|
INVENTIVA
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million...